rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CLRB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Cellectar Biosciences, Inc. Q3 2026 Earnings Call Summary
      Nov 11Yahoo FinanceCLRB
      Cellectar (CLRB) Q3 2026 Earnings Call Transcript

      Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.

      Nov 11The Globe and MailCLRB
      Earnings call transcript: Cellectar posts narrow Q3 2026 EPS miss as trial plans advance
      Nov 10Investing.comCLRB
      Cellectar Biosciences Q3 2026 Earnings Call Transcript
      Nov 10BenzingaCLRB
      Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

      Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy...

      Nov 10Business InsiderCLRB
      Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
      Nov 4Yahoo FinanceCLRB
      Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026

      FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2026, and provide a corporate update on November 10, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Tuesday, November 10, 2026Time:8:30 am Easter

      Nov 2Yahoo FinanceCLRB
      Cellectar reports 8-year remission in lymphoma case study
      Oct 27Investing.comCLRB
      Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
      Oct 27Yahoo FinanceCLRB
      Cellectar reports trial data for cancer drug in rare disease
      Oct 15Investing.comCLRB
      Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia

      Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months Initiation and site selections for Phase 3 confirmatory randomized clinical trial in post-first line, post-BTKi population evaluating Progression-Free Survival as primary endpoint underway; dosing of first patients expected in 1Q27 and application for U.S. accelerated market approval anticipated

      Oct 15Yahoo FinanceCLRB
      Cellectar plans Phase 3 trial, regulatory filing for WM treatment
      Sep 29Investing.comCLRB
      Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
      Sep 29Yahoo FinanceCLRB
      Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Viridian Therapeutics (NASDAQ:VRDN), S

      Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another

      Sep 3BenzingaCLRBVRDN

      This is the newest page. Registered accounts read further back.